Boehringer Ingelheim and Cognizant Unveil Unified Cloud Platform for Faster Patient Therapies
Cognizant and Boehringer Ingelheim have officially launched an all-encompassing technology platform that marks a significant advance in the development of life-changing treatments for patients. Powered by the Veeva Development Cloud, this unified platform melds previously disconnected functions into a streamlined and efficient framework intended to accelerate therapeutic innovations. This announcement, made on March 11, 2025, signifies the completion of the first phase of their collaboration, which began in 2023.
The newly introduced "One Medicine Platform" replaces over 20 outdated systems, creating a cohesive ecosystem for medicinal development processes and data management. This initiative is designed to improve operational efficiency and foster cross-departmental collaboration.
Cognizant, serving as the primary system integrator, initiated the project by co-developing a comprehensive roadmap and implementation workflow focused on agility and efficiency. Their contributions include essential services such as program management, system architecture, integration, and testing, all carried out in close partnership with Syneos Health Consulting and Veeva.
In this initial phase, Cognizant successfully facilitated the integration of clinical data, operational processes, regulatory systems, and quality assurance functions, allowing Boehringer Ingelheim to effectively transition to the new platform. This holistic strategy is anticipated to enhance the workflows of over 15,000 users currently involved in Clinical Development programs.
Looking ahead to Phase Two, Cognizant and Boehringer Ingelheim plan to further enhance clinical operations and integrate additional modules into the regulatory framework, advancing their goal of efficiency.
Oliver Fink, Head of Learning, Processes & Digitalization, Global Quality Medicine at Boehringer Ingelheim, stated, "For years, we were reliant on multiple vendor systems that could not communicate effectively, resulting in cumbersome workflows. With the launch of our One Medicine Platform, we are revolutionizing our medicinal development strategies and significantly elevating our operational efficiency."
Echoing this sentiment, Gagan Syal, Head of Life Sciences for EMEA and APAC at Cognizant, expressed pride in reaching this important milestone. "This new system is set to resolve data-related challenges and delays, ultimately facilitating a quicker go-to-market strategy for Boehringer Ingelheim's products. Our close cooperation has enabled the successful execution of this project in record time."
Cognizant is dedicated to evolving modern businesses, aiding clients in the modernization of technology, reimagining processes, and refining experiences, ensuring they stay competitive in today's rapidly changing landscape. More information can be found at www.cognizant.com or via Twitter @cognizant.
Founded in 1885, Boehringer Ingelheim is a biopharmaceutical enterprise committed to both human and animal health, maintaining independence since inception. The company heavily invests in research and development, concentrating on innovative therapies to meet high medical needs. The company employs over 53,500 individuals and operates across more than 130 markets, committed to building a healthier and more equitable future. For further details, visit https://www.boehringer-ingelheim.com.
The newly introduced "One Medicine Platform" replaces over 20 outdated systems, creating a cohesive ecosystem for medicinal development processes and data management. This initiative is designed to improve operational efficiency and foster cross-departmental collaboration.
Cognizant, serving as the primary system integrator, initiated the project by co-developing a comprehensive roadmap and implementation workflow focused on agility and efficiency. Their contributions include essential services such as program management, system architecture, integration, and testing, all carried out in close partnership with Syneos Health Consulting and Veeva.
In this initial phase, Cognizant successfully facilitated the integration of clinical data, operational processes, regulatory systems, and quality assurance functions, allowing Boehringer Ingelheim to effectively transition to the new platform. This holistic strategy is anticipated to enhance the workflows of over 15,000 users currently involved in Clinical Development programs.
Looking ahead to Phase Two, Cognizant and Boehringer Ingelheim plan to further enhance clinical operations and integrate additional modules into the regulatory framework, advancing their goal of efficiency.
Oliver Fink, Head of Learning, Processes & Digitalization, Global Quality Medicine at Boehringer Ingelheim, stated, "For years, we were reliant on multiple vendor systems that could not communicate effectively, resulting in cumbersome workflows. With the launch of our One Medicine Platform, we are revolutionizing our medicinal development strategies and significantly elevating our operational efficiency."
Echoing this sentiment, Gagan Syal, Head of Life Sciences for EMEA and APAC at Cognizant, expressed pride in reaching this important milestone. "This new system is set to resolve data-related challenges and delays, ultimately facilitating a quicker go-to-market strategy for Boehringer Ingelheim's products. Our close cooperation has enabled the successful execution of this project in record time."
About Cognizant
Cognizant is dedicated to evolving modern businesses, aiding clients in the modernization of technology, reimagining processes, and refining experiences, ensuring they stay competitive in today's rapidly changing landscape. More information can be found at www.cognizant.com or via Twitter @cognizant.
About Boehringer Ingelheim
Founded in 1885, Boehringer Ingelheim is a biopharmaceutical enterprise committed to both human and animal health, maintaining independence since inception. The company heavily invests in research and development, concentrating on innovative therapies to meet high medical needs. The company employs over 53,500 individuals and operates across more than 130 markets, committed to building a healthier and more equitable future. For further details, visit https://www.boehringer-ingelheim.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.